Table of Contents Author Guidelines Submit a Manuscript
Enzyme Research
Volume 2011, Article ID 194857, 5 pages
http://dx.doi.org/10.4061/2011/194857
Review Article

Autotaxin: Its Role in Biology of Melanoma Cells and as a Pharmacological Target

1Department of Therapy Monitoring and Pharmacogenetics, Medical University of Gdańsk, Debinki 7, 80-211 Gdańsk, Poland
2Laboratory of Molecular and Cellular Nephrology, Mossakowski Medical Research Center, Polish Academy of Sciences, 80-211 Gdańsk, Poland

Received 29 August 2010; Accepted 12 January 2011

Academic Editor: Jun-Mo Yang

Copyright © 2011 Maciej Jankowski. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Stefan, S. Jansen, and M. Bollen, “NPP-type ectophosphodiesterases: unity in diversity,” Trends in Biochemical Sciences, vol. 30, no. 10, pp. 542–550, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. M. L. Stracke, A. Arestad, M. Levine, H. C. Krutzsch, and L. A. Liotta, “Autotaxin is an N-linked glycoprotein but the sugar moieties are not needed for its stimulation of cellular motility,” Melanoma Research, vol. 5, no. 4, pp. 203–209, 1995. View at Google Scholar · View at Scopus
  3. S. Jansen, C. Stefan, J. W. M. Creemers et al., “Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D,” Journal of Cell Science, vol. 118, no. 14, pp. 3081–3089, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. L. M. Yuelling and B. Fuss, “Autotaxin (ATX): a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties,” Biochimica et Biophysica Acta, vol. 1781, no. 9, pp. 525–530, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. K. Nakanaga, K. Hama, and J. Aoki, “Autotaxin-An LPA producing enzyme with diverse functions,” Journal of Biochemistry, vol. 148, no. 1, pp. 13–24, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. L. A. Van Meeteren, P. Ruurs, E. Christodoulou et al., “Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate,” Journal of Biological Chemistry, vol. 280, no. 22, pp. 21155–21161, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. T. Sugiura, S. Nakane, S. Kishimoto, K. Waku, Y. Yoshioka, and A. Tokumura, “Lysophosphatidic acid, a growth factor-like lipid, in the saliva,” Journal of Lipid Research, vol. 43, no. 12, pp. 2049–2055, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Tanaka, Y. Kishi, Y. Takanezawa, Y. Kakehi, J. Aoki, and H. Arai, “Prostatic acid phosphatase degrades lysophosphatidic acid in seminal plasma,” FEBS Letters, vol. 571, no. 1–3, pp. 197–204, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. A. Masuda, K. Nakamura, K. Izutsu et al., “Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma,” British Journal of Haematology, vol. 143, no. 1, pp. 60–70, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. K. Nakamura, M. Nangaku, R. Ohkawa et al., “Analysis of serum and urinary lysophospholipase D/autotaxin in nephrotic syndrome,” Clinical Chemistry and Laboratory Medicine, vol. 46, no. 1, pp. 150–151, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. K. Nakamura, K. Igarashi, R. Ohkawa et al., “Autotaxin enzyme immunoassay in human cerebrospinal fluid samples,” Clinica Chimica Acta, vol. 405, no. 1-2, pp. 160–162, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. S. Jansen, M. Andries, K. Vekemans, H. Vanbilloen, A. Verbruggen, and M. Bollen, “Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells,” Cancer Letters, vol. 284, no. 2, pp. 216–221, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. M. Tanaka, S. Okudaira, Y. Kishi et al., “Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid,” Journal of Biological Chemistry, vol. 281, no. 35, pp. 25822–25830, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. S. E. Alvarez, S. Milstien, and S. Spiegel, “Autocrine and paracrine roles of sphingosine-1-phosphate,” Trends in Endocrinology and Metabolism, vol. 18, no. 8, pp. 300–307, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. H. Fyrst and J. D. Saba, “An update on sphingosine-1-phosphate and other sphingolipid mediators,” Nature Chemical Biology, vol. 6, no. 7, pp. 489–497, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. T. Clair, H. Y. Lee, L. A. Liotta, and M. L. Stracke, “Autotaxin is an exoenzyme possessing 5'-nucleotide phosphodiesterase/ATP pyrophosphatase and ATPase activities,” Journal of Biological Chemistry, vol. 272, no. 2, pp. 996–1001, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Gijsbers, J. Aoki, H. Arai, and M. Bollen, “The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site,” FEBS Letters, vol. 538, no. 1–3, pp. 60–64, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. L. A. van Meeteren and W. H. Moolenaar, “Regulation and biological activities of the autotaxin-LPA axis,” Progress in Lipid Research, vol. 46, no. 2, pp. 145–160, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. J. Aoki, A. Inoue, and S. Okudaira, “Two pathways for lysophosphatidic acid production,” Biochimica et Biophysica Acta, vol. 1781, no. 9, pp. 513–518, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. S. Okudaira, H. Yukiura, and J. Aoki, “Biological roles of lysophosphatidic acid signaling through its production by autotaxin,” Biochimie, vol. 92, no. 6, pp. 698–706, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. K. Hama, K. Bandoh, Y. Kakehi, J. Aoki, and H. Arai, “Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors,” FEBS Letters, vol. 523, no. 1–3, pp. 187–192, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Lee, IN. D. Jung, S. W. Nam et al., “Enzymatic activation of autotaxin by divalent cations without EF-hand loop region involvement,” Biochemical Pharmacology, vol. 62, no. 2, pp. 219–224, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. J. A. Boutin and G. Ferry, “Autotaxin,” Cellular and Molecular Life Sciences, vol. 66, no. 18, pp. 3009–3021, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. S. Jansen, M. Andries, R. Derua, E. Waelkens, and M. Bollen, “Domain interplay mediated by an essential disulfide linkage is critical for the activity and secretion of the metastasis-promoting enzyme autotaxin,” Journal of Biological Chemistry, vol. 284, no. 21, pp. 14296–14302, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. E. Koh, R. W. Bandle, D. D. Roberts, M. L. Stracke, and T. Clair, “Novel point mutations attenuate autotaxin activity,” Lipids in Health and Disease, vol. 8, article no. 4, 2009. View at Publisher · View at Google Scholar · View at PubMed
  26. L. A. Van Meeteren, P. Ruurs, C. Stortelers et al., “Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development,” Molecular and Cellular Biology, vol. 26, no. 13, pp. 5015–5022, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. JI. W. Choi, C. W. Lee, and J. Chun, “Biological roles of lysophospholipid receptors revealed by genetic null mice: an update,” Biochimica et Biophysica Acta, vol. 1781, no. 9, pp. 531–539, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. S. Liu, M. Umezu-Goto, M. Murph et al., “Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases,” Cancer Cell, vol. 15, no. 6, pp. 539–550, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. M. L. Stracke, H. C. Krutzsch, E. J. Unsworth et al., “Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein,” Journal of Biological Chemistry, vol. 267, no. 4, pp. 2524–2529, 1992. View at Google Scholar · View at Scopus
  30. M. Umezu-Goto, Y. Kishi, A. Taira et al., “Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production,” Journal of Cell Biology, vol. 158, no. 2, pp. 227–233, 2002. View at Google Scholar · View at Scopus
  31. C. G. Gaetano, N. Samadi, J. L. Tomsig, T. L. Macdonald, K. R. Lynch, and D. N. Brindley, “Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells,” Molecular Carcinogenesis, vol. 48, no. 9, pp. 801–809, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. M. K. Altman, V. Gopal, W. Jia et al., “Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid,” Molecular Cancer, vol. 9, article no. 140, 2010. View at Publisher · View at Google Scholar · View at PubMed
  33. A. D. Singh, K. Sisley, Y. Xu et al., “Reduced expression of autotaxin predicts survival in uveal melanoma,” British Journal of Ophthalmology, vol. 91, no. 10, pp. 1385–1392, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. K. Hama, J. Aoki, M. Fukaya et al., “Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA,” Journal of Biological Chemistry, vol. 279, no. 17, pp. 17634–17639, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. H. Y. Lee, G. U. Bae, IN. D. Jung et al., “Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase γ in human melanoma cells,” FEBS Letters, vol. 515, no. 1–3, pp. 137–140, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. IN. D. Jung, J. Lee, S. Y. Yun et al., “Cdc42 and Rac1 are necessary for autotaxin-induced tumor cell motility in A2058 melanoma cells,” FEBS Letters, vol. 532, no. 3, pp. 351–356, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. IN. D. Jung, J. Lee, K. B. Lee et al., “Activation of p21-activated kinase 1 is required for lysophosphatidic acid-induced focal adhesion kinase phosphorylation and cell motility in human melanoma A2058 cells,” European Journal of Biochemistry, vol. 271, no. 8, pp. 1557–1565, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. J. Lee, I. D. Jung, C. G. Park, J. W. Han, and H. Y. Lee, “Autotaxin stimulates urokinase-type plasminogen activator expression through phosphoinositide 3-kinase-Akt-necrosis factor kappa B signaling cascade in human melanoma cells,” Melanoma Research, vol. 16, no. 5, pp. 445–452, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. E. Gendaszewska-Darmach, “Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promissing targets in therapies of cancer and other diseases,” Acta Biochimica Polonica, vol. 55, no. 2, pp. 227–240, 2008. View at Google Scholar · View at Scopus
  40. T. Clair, E. Koh, M. Ptaszynska et al., “L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin,” Lipids in Health and Disease, vol. 4, article 5, 2005. View at Publisher · View at Google Scholar · View at PubMed
  41. D. L. Bakera, Y. Fujiwara, K. R. Pigg et al., “Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis,” Journal of Biological Chemistry, vol. 281, no. 32, pp. 22786–22793, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. G. D. Prestwich, J. Gajewiak, H. Zhang, X. Xu, G. Yang, and M. Serban, “Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer,” Biochimica et Biophysica Acta, vol. 1781, no. 9, pp. 588–594, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. A. Uchiyama, M. Mukai, Y. Fujiwara et al., “Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid,” Biochimica et Biophysica Acta, vol. 1771, no. 1, pp. 103–112, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. G. Jiang, Y. Xu, Y. Fujiwara et al., “α-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA,” ChemMedChem, vol. 2, no. 5, pp. 679–690, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. Y. Fujiwara, “Cyclic phosphatidic acid—a unique bioactive phospholipid,” Biochimica et Biophysica Acta, vol. 1781, no. 9, pp. 519–524, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. H. M. H. G. Albers, A. Dong, L. A. Van Meeteren et al., “Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 16, pp. 7257–7262, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. J. Gierse, A. Thorarensen, K. Beltey et al., “A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 1, pp. 310–317, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. L. P. Saunders, A. Ouellette, R. Bandle et al., “Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion,” Molecular Cancer Therapeutics, vol. 7, no. 10, pp. 3352–3362, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. A. B. Hoeglund, A. L. Howard, I. W. Wanjala, T. C. T. Pham, A. L. Parrill, and D. L. Baker, “Characterization of non-lipid autotaxin inhibitors,” Bioorganic and Medicinal Chemistry, vol. 18, no. 2, pp. 769–776, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. A. B. Hoeglund, H. E. Bostic, A. L. Howard et al., “Optimization of a pipemidic acid autotaxin inhibitor,” Journal of Medicinal Chemistry, vol. 53, no. 3, pp. 1056–1066, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. K. Ueda, M. Yoshihara, M. Nakao et al., “Evaluation of inhibitory actions of flavonols and related substances on lysophospholipase D activity of serum autotaxin by a convenient assay using a chromogenic substrate,” Journal of Agricultural and Food Chemistry, vol. 58, no. 10, pp. 6053–6063, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. J. E. Day, T. Hall, L. E. Pegg, T. E. Benson, J. Hausmann, and S. Kamtekar, “Crystallization and preliminary X-ray diffraction analysis of rat autotaxin,” Acta Crystallographica Section F, vol. 66, no. 9, pp. 1127–1129, 2010. View at Publisher · View at Google Scholar · View at PubMed
  53. J. Hausmann, E. Christodoulou, M. Kasiem et al., “Mammalian cell expression, purification, crystallization and microcrystal data collection of autotaxin/ENPP2, a secreted mammalian glycoprotein,” Acta Crystallographica Section F, vol. 66, no. 9, pp. 1130–1135, 2010. View at Publisher · View at Google Scholar · View at PubMed